Royalty Pharma dividend and valuation

RPRX · NASDAQ · USD

Compare Royalty Pharma
$68.83Change from previous close: −0.69%Absolute change: −$0.48

Close · November 16, 2026

Valuation

Royalty Pharma paid $0.94 per share in dividends over the last 12 months (yield 1.4%). Last ex-dividend date: November 13, 2026. The P/E ratio is 45.3. The average price target of 8 analysts is $72.00.

Data as of November 16, 2026

Royalty Pharma compared with similar companies

Royalty Pharma's P/E (trailing 12 months): 45.3, +15% against the median of a group of 6 similar companies (39.3).

Royalty Pharma's metrics compared with similar companies
MetricRoyalty PharmaMedian25th–75th percentileBand
P/E (trailing 12 months)45.339.321.9 – 51.4Middle
Forward P/E11.722.914.6 – 33.8Low
EV/EBITDA24.824.820.8 – 33.0Middle
Price/book4.528.175.33 – 14.4Low
Price/sales15.212.67.59 – 16.9Middle
Gross margin99.8%76.7%28.0% – 86.9%High
Operating margin64.4%17.8%-68.1% – 31.4%High
Net margin25.7%6.7%-19.9% – 28.7%Middle
ROE12.1%7.8%-21.5% – 21.0%Middle
Debt/equity0.880.350.02 – 0.73High

Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.

TickerLandia analysisHow it is calculated

Companies in the group: same industry, similar size

Royalty Pharma: valuation over time

On the latest fiscal year's earnings (2025), Royalty Pharma's P/E today is 38.6, above the median of its last 5 fiscal years (21.7; between 11.1 and 37.9 from 2020 to 2025). Relative to earnings, the stock costs more than it used to. The dividend yield (1.4%) is below the median of the last 6 fiscal years (2.1%).

Royalty Pharma P/E and dividend yield at each fiscal year end
Fiscal yearPrice at year endEarnings per shareP/EDividend per shareYield
2025$38.64$1.7821.7$0.882.3%
2024$25.51$1.9113.3$0.843.3%
2023$28.09$2.5311.1$0.802.8%
2022$39.52$0.10—$0.761.9%
2021$39.85$1.4926.7$0.681.7%
2020$50.05$1.3237.9$0.300.6%

TickerLandia calculation: closing price on the last trading day of the fiscal year divided by diluted earnings per share from the annual report (positive earnings only); yield = dividend per share for the year divided by the same price. Prices adjusted for splits. Today's P/E is today's price divided by the latest fiscal year's earnings per share, so it compares with the years above; today's yield uses dividends over the last 12 months.

TickerLandia analysisHow it is calculated

Other metrics

Valuation multiples

Market cap
$39.85B
Enterprise value
$41.86B
PEG
2.10
EV/revenue
16.0

Profitability and growth

ROA
5.4%
ROIC
5.3%
Revenue growth (year over year)
13.3%
Earnings growth (year over year)
-50.8%

Financial health

Total cash
$544.86M
Total debt
$8.59B
Current ratio
1.29
Quick ratio
1.29
Altman Z-Score
1.93
Piotroski F-Score
6.00

Dividends

Annual dividend per share
$0.94
Dividend yield
1.4%
Payout ratio
61.4%
Ex-dividend date
November 13, 2026

Analysts and estimates

Average price target
$72.00
Median price target
$74.00
High price target
$78.00
Low price target
$66.00
Analysts with a price target
8
Consensus
Buy
Forward EPS
$5.91
EPS estimate, current year
$5.39

Shares and trading

Beta
0.36
Average volume
3.17M
Shares outstanding
445.27M
Float
417.1M
Institutional ownership
88.1%
Insider ownership
6.9%
Short interest (% of float)
3.0%
Short ratio (days)
4.05